2. Antibody-drug Conjugate/ADC Related
  3. Antibody-Drug Conjugates (ADCs)
  4. Lupartumab Amadotin

Lupartumab Amadotin  (Synonyms: BAY 1129980; Anti-C4.4a antibody-drug conjugates)

Cat. No.: HY-P99719
Handling Instructions Technical Support

Lupartumab Amadotin (BAY 1129980) is an antibody–drug conjugate (ADC) consisting of a fully human C4.4A (LYPD3)-targeting mAb (BAY 1135626) (HY-147281) conjugated to a novel, highly potent derivative of the microtubule-disrupting cytotoxic drug auristatin via a noncleavable alkyl hydrazide linker. Lupartumab Amadotin can be used for the research of non-small cell lung cancer.

For research use only. We do not sell to patients.

Lupartumab Amadotin Chemical Structure

Lupartumab Amadotin Chemical Structure

CAS No. : 1640972-00-4

Size Price Stock
1 mg Ask For Quote & Lead Time
5 mg Ask For Quote & Lead Time
10 mg Ask For Quote & Lead Time

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Lupartumab Amadotin Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Lupartumab Amadotin (BAY 1129980) is an antibody–drug conjugate (ADC) consisting of a fully human C4.4A (LYPD3)-targeting mAb (BAY 1135626) (HY-147281) conjugated to a novel, highly potent derivative of the microtubule-disrupting cytotoxic drug auristatin via a noncleavable alkyl hydrazide linker. Lupartumab Amadotin can be used for the research of non-small cell lung cancer[1].

IC50 & Target

human C4.4A[1]
In Vitro

Lupartumab Amadotin (BAY 1129980; 0-2 nM; 72 h) demonstrates potent antiproliferative efficacy in cell lines endogenously expressing C4.4A and inhibits proliferation of C4.4A-transfected A549 lung cancer cells showing selectivity compared with a nontargeted control ADC[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Lupartumab Amadotin Related Antibodies

Cell Viability Assay[1]

Cell Line: hC4.4A:A549, mock:A549, NCI-H292, FaDu, NCI-H322, SCaBER and SCC-4 cells
Concentration: 0-2 nM
Incubation Time: 72 h
Result: High potency at subnanomolar range (IC50=0.05 nM) was observed in hC4.4A:A549 lung cancer cells, a remarkable selectivity (over 1,000-fold) compared with mock:A549 cells was observed. Showed high potency with IC50s at single- to double-digit nanomolar range and even at subnanomolar range (IC50 of 0.6 nM) in NCI-H292 lung cancer cell line.
In Vivo

Lupartumab Amadotin (BAY 1129980; 1.9-15 mg/kg; i.v.; Q4D×3) shows antitumor efficacy in the C4.4A-positive NCI-H292 and NCI-H322 NSCLC xenograft model[1].
Lupartumab Amadotin (BAY 1129980; 7.5 and 15 mg/kg; i.v.; Q4D×3) shows C4.4A target-dependent antitumor efficacy in NSCLC patient-derived xenograft (PDX) models[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: NMRI nu/nu mice, C4.4A-positive NCI-H292 human NSCLC xenograft model[1]
Dosage: 1.9, 3.75, 7.5 and 15 mg/kg
Administration: IV, Q4D×3
Result: Halted tumor growth dose dependently with a minimum effective dose (MED) of 1.9 mg/kg. The first treatment cycle with 15 mg/kg drug (Q4D×3) resulted in a marked delay of tumor growth with a significantly reduced tumor volume, as compared to vehicle, Cisplatin (HY-17394), or control ADC.
CAS No.
SMILES

[Lupartumab Amadotin]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Lupartumab Amadotin Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Lupartumab Amadotin1640972-00-4BAY 1129980 Anti-C4.4a antibody-drug conjugatesBAY1129980BAY-1129980Antibody-Drug Conjugates (ADCs)Antibody-Drug Conjugatesnon-small cell lung cancerA549NCI-H292FaDuNCI-H322SCaBERSCC-4NMRI nu/nu miceNSCLCInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Lupartumab Amadotin
Cat. No.:
HY-P99719
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (0 KB) Français - FR (0 KB) Deutsch - DE (0 KB) Norwegian - NO (0 KB) Español - ES (0 KB) Swedish - SV (0 KB) Italian - IT (0 KB) Portuguese - PT (0 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.